Adjuvant Temozolomide Improves Overall Survival in Anaplastic Glioma Subtype

Share this content:
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.

Adjuvant temozolomide therapy after radiotherapy may significantly improve overall and progression-free survival (OS and PFS, respectively) among patients with newly diagnosed, non-co-deleted anaplastic glioma, according to a study published in The Lancet.1

Evidence from previous studies demonstrated that administering chemotherapy to patients with chemotherapy-sensitive brain malignancies after radiotherapy did not improve OS.

For the CATNON phase 3 trial (ClinicalTrials.gov Identifier: NCT00626990), researchers enrolled 745 patients with anaplastic glioma and randomly assigned them to receive radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant temozolomide 150 to 200mg/m2 given on days 1 to 5 for 12 4-week cycles, or to receive radiotherapy with concurrent temozolomide 75mg/m2 daily, alone or with adjuvant temozolomide.

At the median follow-up of 27 months, 46% of patients had disease progression and 30% had died. The adjusted hazard ratio (HR) for OS was 0.65 (99-145% CI, 0.45-0.93).

The adjuvant temozolomide group had a 5-year OS of 55.9% (95% CI, 47.2-63.8) vs 44.1% (95% CI, 36.3-51.6) among others.

The adjuvant temozolomide group had a 5-year PFS of 43.1% (95% CI, 35.0-50.9) vs 24.3% (95% CI, 17.7-31.6) among others.

Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.

RELATED: Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma

The authors concluded that “further follow-up and tissue studies are needed to establish the efficacy of concurrent temozolomide chemotherapy and the effects of molecular signatures on outcome.”

Reference

  1. van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomized, open-label intergroup study. Lancet. 2017 Aug 8. doi: 10.1016/S0140-6736(17)31442-3 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters